Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
Status:
Unknown status
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Patients with liver cancer will receive interventional therapy plus radiotherapy. Maintenance
Sorafenib will be taken after the completion of radiotherapy. Hypothesis of the current study
is that Sorafenib as a maintenance therapy is safe and superior to radiotherapy combined with
interventional therapy in terms of survival in comparison to historical data.